MIGS Devices Continue to Expand Use of Glaucoma Surgery

Source: Market Scope

Minimally invasive glaucoma surgery (MIGS) stents account for nearly half of all glaucoma surgical device revenue in 2019, according to a Market Scope report.

Market penetration of these stents over the past 5 years has been impressive, but the voluntary recall of the Alcon CyPass in 2018 slowed the adoption rate. It also opened the door for other surgical and laser treatments.

Market Scope examines this shifting landscape in its newly published “2019 Glaucoma Surgical Device Market Report.”

Glaucoma is the world’s second leading cause of blindness. The disease affects nearly 100 million people around the globe, according to Market Scope estimates. Another 41 million have ocular hypertension, a condition that often precedes glaucoma.

There are four FDA-approved MIGS stents in the United States: the Glaukos iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. The number of participants will grow soon with the expected approval of the Santen PreserFlo Microshunt.

Medication is the most frequently prescribed treatment for mild to moderate stages of glaucoma. Surgery typically is chosen only when medications are no longer able to control the disease. Only 2% of diagnosed glaucoma patients globally were treated surgically in 2018.

The “2019 Glaucoma Surgical Device Market Report” analyzes renewed interest in other surgical and laser options.

Laser treatments are the most frequently chosen option to treat glaucoma patients who are no longer responding to medication. Laser options include selective laser trabeculoplasty and cyclophotocoagulation lasers (BVI/Endo Optiks, Ellex, Iridex, LightMed, Optotek). A large number of disruptive early-stage laser developments have the potential to increase their appeal.

Market Scope’s report looks at renewed interest in canal surgery devices, including the Ellex ABiC for canaloplasty, Sight Sciences OMNI, NeoMedix Trabectome, and New World Medical Kahook Dual Blade (KDB). These companies are touting an advantage over MIGS stents because no hardware is left behind in the eye that potentially could cause the type of problem that led to the CyPass recall. 

All these developments are expected to drive global revenue to $1.7 billion by 2024, an increase from just over $700 million in 2019.

Glaukos is expected to dominate the market in 2019, with a third of total revenue. Eight companies will account for nearly 80 percent of revenue. They are Glaukos, New World Medical, Allergan, Ivantis, Ellex, Alcon, J&J Vision, and Iridex.

Market Scope’s 2019 Glaucoma Surgical Device Market Report: A Global Analysis for 2018 to 2024 was published in August.

Related Content